Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1975 Dec;56(6):1650–1662. doi: 10.1172/JCI108247

Williams trait. Human kininogen deficiency with diminished levels of plasminogen proactivator and prekallikrein associated with abnormalities of the Hageman factor-dependent pathways.

R W Colman, A Bagdasarian, R C Talamo, C F Scott, M Seavey, J A Guimaraes, J V Pierce, A P Kaplan
PMCID: PMC333144  PMID: 1202089

Abstract

An asymptomatic woman (Ms. Williams) was found to have a severe abnormality in the surface-activated intrinsic coagulation, fibrinolytic, and kinin-generating pathways. Assays for known coagulation factors were nromal while Fletcher factor (pre-kallikrein) was 45%, insufficient to account for the observed markedly prolonged partial thromboplastin time. Plasminogen proactivator was present at 20% of normal levels and addition of highly purified plasminogen proactivator containing 10% plasminogen activator partially corrected the coagulation and fibrinolytic abnormalities but not the kinin-generating defect. This effect was due to its plasminogen activator content. In addition, Williams trait plasma failed to convert prekallilrein to lakkilrein or release kinin upon incubation with kaolin. Kininogen antigen was undetectable. When normal plasma was fractionated to identify the factor that corrects all the abnormalities in Williams trait plasma, the Williams factor was identified as a form of kininogen by its behavior on ion exchange chromatography, gel filtration, disc gel electrophoresis, and elution from an anti-low molecular weight kininogen immunoadsorbent. High molecular weight kininogen as well as a subfraction of low molecular weight kininogen, possessed this corrective activity while the bulk of low molecular weight kininogen functioned only as a kallikrein substrate. Kininogen therefore is a critical factor required for the functioning of Hageman factor-dependent coagulation and fibrinolysis and for the activation of prekallikrein.

Full text

PDF
1650

Images in this article

1655Image
on p.1655
1656Image
on p.1656
1659Image
on p.1659

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ALKJAERSIG N., FLETCHER A. P., SHERRY S. xi-Aminocaproic acid: an inhibitor of plasminogen activation. J Biol Chem. 1959 Apr;234(4):832–837. [PubMed] [Google Scholar]
  2. Axén R., Porath J., Ernback S. Chemical coupling of peptides and proteins to polysaccharides by means of cyanogen halides. Nature. 1967 Jun 24;214(5095):1302–1304. doi: 10.1038/2141302a0. [DOI] [PubMed] [Google Scholar]
  3. BACHMANN F., DUCKERT F., KOLLER F. The Stuart-Prower factor assay and its clinical significance. Thromb Diath Haemorrh. 1958 May 1;2(1-2):24–38. [PubMed] [Google Scholar]
  4. BELL W. N., ALTON H. G. Christmas disease associated with factor VII deficiency; case report with family survey. Br Med J. 1955 Feb 5;1(4909):330–331. doi: 10.1136/bmj.1.4909.330. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bagdasarian A., Lahiri B., Colman R. W. Origin of the high molecular weight activator of prekallikrein. J Biol Chem. 1973 Nov 25;248(22):7742–7747. [PubMed] [Google Scholar]
  6. Bagdasarian A., Lahiri B., Talamo R. C., Wong P., Colman R. W. Immunochemical studies of plasma kallikrein. J Clin Invest. 1974 Dec;54(6):1444–1454. doi: 10.1172/JCI107892. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Bagdasarian A., Talamo R. C., Colman R. W. Isolation of high molecular weight activators of human plasma prekallikrein. J Biol Chem. 1973 May 25;248(10):3456–3463. [PubMed] [Google Scholar]
  8. CLAUSS A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol. 1957 Apr;17(4):237–246. doi: 10.1159/000205234. [DOI] [PubMed] [Google Scholar]
  9. Cochrane C. G., Revak S. D., Wuepper K. D. Activation of Hageman factor in solid and fluid phases. A critical role of kallikrein. J Exp Med. 1973 Dec 1;138(6):1564–1583. doi: 10.1084/jem.138.6.1564. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Colman R. W., Mason J. W., Sherry S. The kallikreinogen-kallikrein enzyme system of human plasma. Assay of components and observations in disease states. Ann Intern Med. 1969 Oct;71(4):763–773. doi: 10.7326/0003-4819-71-4-763. [DOI] [PubMed] [Google Scholar]
  11. Colman R. W., Mattler L., Sherry S. Studies on the prekallikrein (kallikreinogen)--kallikrein enzyme system of human plasma. I. Isolation and purification of plasma kallikreins. J Clin Invest. 1969 Jan;48(1):11–22. doi: 10.1172/JCI105959. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Deutsch D. G., Mertz E. T. Plasminogen: purification from human plasma by affinity chromatography. Science. 1970 Dec 4;170(3962):1095–1096. doi: 10.1126/science.170.3962.1095. [DOI] [PubMed] [Google Scholar]
  13. Garvey M. B., Black J. M. The detection of fibrinogen-fibrin degradation products by means of a new antibody-coated latex particle. J Clin Pathol. 1972 Aug;25(8):680–682. doi: 10.1136/jcp.25.8.680. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Habal F. M., Movat H. Z., Burrowes C. E. Isolation of two functionally different kininogens from human plasma--separation from proteinase inhibitors and interaction with plasma kallikrein. Biochem Pharmacol. 1974 Aug 15;23(16):2291–2303. doi: 10.1016/0006-2952(74)90558-9. [DOI] [PubMed] [Google Scholar]
  15. IATRIDIS S. G., FERGUSON J. H. Actie Hageman factor: a plasma lysokinase of the human fibrinolytic system. J Clin Invest. 1962 Jun;41:1277–1287. doi: 10.1172/JCI104590. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. IVERSEN T., BASTRUP-MADSEN P. Congenital familial deficiency of factor V (parahaemophilia) combined with deficiency of antihaemophilic globulin. Br J Haematol. 1956 Jul;2(3):265–275. doi: 10.1111/j.1365-2141.1956.tb06698.x. [DOI] [PubMed] [Google Scholar]
  17. Johnston A. R., Cochrane C. G., Revak S. D. The relationship between PF-DIL and activated human Hageman factor. J Immunol. 1974 Jul;113(1):103–109. [PubMed] [Google Scholar]
  18. Kaplan A. P., Austen K. F. A pre-albumin activator of prekallikrein. J Immunol. 1970 Oct;105(4):802–811. [PubMed] [Google Scholar]
  19. Kaplan A. P., Austen K. F. A prealbumin activator of prekallikrein. II. Derivation of activators of prekallikrein from active Hageman factor by digestion with plasmin. J Exp Med. 1971 Apr 1;133(4):696–712. doi: 10.1084/jem.133.4.696. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Kaplan A. P., Austen K. F. The fibrinolytic pathway of human plasma. Isolation and characterization of the plasminogen proactivator. J Exp Med. 1972 Dec 1;136(6):1378–1393. doi: 10.1084/jem.136.6.1378. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. LEWIS M. L., WARE A. G. A one-stage method for the determination of accelerator globulin. Proc Soc Exp Biol Med. 1953 Dec;84(3):640–643. doi: 10.3181/00379727-84-20738. [DOI] [PubMed] [Google Scholar]
  22. MARGOLIS J. Activation of plasma by contact with glass: evidence for a common reaction which releases plasma kinin and initiates coagulation. J Physiol. 1958 Nov 10;144(1):1–22. doi: 10.1113/jphysiol.1958.sp006082. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Mancini G., Carbonara A. O., Heremans J. F. Immunochemical quantitation of antigens by single radial immunodiffusion. Immunochemistry. 1965 Sep;2(3):235–254. doi: 10.1016/0019-2791(65)90004-2. [DOI] [PubMed] [Google Scholar]
  24. NIEWIAROWSKI S., PROU-WARTELLE O. [Role of the contact factor (Hageman factor) in fibrinolysis]. Thromb Diath Haemorrh. 1959 Sep 1;3:593–603. [PubMed] [Google Scholar]
  25. OUCHTERLONY O. Antigen-antibody reactions in gels. IV. Types of reactions in coordinated systems of diffusion. Acta Pathol Microbiol Scand. 1953;32(2):230–240. [PubMed] [Google Scholar]
  26. OWREN P. A., AAS K. The control of dicumarol therapy and the quantitative determination of prothrombin and proconvertin. Scand J Clin Lab Invest. 1951;3(3):201–208. doi: 10.3109/00365515109060600. [DOI] [PubMed] [Google Scholar]
  27. PROCTOR R. R., RAPAPORT S. I. The partial thromboplastin time with kaolin. A simple screening test for first stage plasma clotting factor deficiencies. Am J Clin Pathol. 1961 Sep;36:212–219. doi: 10.1093/ajcp/36.3.212. [DOI] [PubMed] [Google Scholar]
  28. Pierce J. V. Structural features of plasma kinins and kininogens. Fed Proc. 1968 Jan-Feb;27(1):52–57. [PubMed] [Google Scholar]
  29. RATNOFF O. D., COLOPY J. E. A familial hemorrhagic trait associated with a deficiency of a clot-promoting fraction of plasma. J Clin Invest. 1955 Apr;34(4):602–613. doi: 10.1172/JCI103109. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. RATNOFF O. D., DAVIE E. W., MALLETT D. L. Studies on the action of Hageman factor: evidence that activated Hageman factor in turn activates plasma thromboplastin antecedent. J Clin Invest. 1961 May;40:803–819. doi: 10.1172/JCI104314. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. ROSENTHAL R. L., DRESKIN O. H., ROSENTHAL N. New hemophilia-like disease caused by deficiency of a third plasma thromboplastin factor. Proc Soc Exp Biol Med. 1953 Jan;82(1):171–174. doi: 10.3181/00379727-82-20057. [DOI] [PubMed] [Google Scholar]
  32. SIEGELMAN A. M., CARLSON A. S., ROBERTSON T. Investigation of serum trypsin and related substances. I. The quantitative demonstration of trypsinlike activity in human blood serum by a micromethod. Arch Biochem Biophys. 1962 Apr;97:159–163. doi: 10.1016/0003-9861(62)90058-9. [DOI] [PubMed] [Google Scholar]
  33. Saito H., Ratnoff O. D., Waldmann R., Abraham J. P. Fitzgerald Trait: Deficiency of a Hitherto Unrecognized Agent, Fitzgerald Factor, Participating in Surface-Mediated Reactions of Clotting, Fibrinolysis, Generation of Kinins, and the Property of Diluted Plasma Enhancing Vascular Permeability (PF/Dil). J Clin Invest. 1975 May;55(5):1082–1089. doi: 10.1172/JCI108009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Schreiber A. D., Kaplan A. P., Austen K. F. Plasma inhibitors of the components of the fibrinolytic pathway in man. J Clin Invest. 1973 Jun;52(6):1394–1401. doi: 10.1172/JCI107312. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Spragg J., Austen K. F. the preparation of human kininogen. II. Further characterization of purified human kininogen. J Immunol. 1971 Dec;107(6):1512–1519. [PubMed] [Google Scholar]
  36. Talamo R. C., Haber E., Austen K. F. A radioimmunoassay for bradykinin in plasma and synovial fluid. J Lab Clin Med. 1969 Nov;74(5):816–827. [PubMed] [Google Scholar]
  37. Weber K., Osborn M. The reliability of molecular weight determinations by dodecyl sulfate-polyacrylamide gel electrophoresis. J Biol Chem. 1969 Aug 25;244(16):4406–4412. [PubMed] [Google Scholar]
  38. Weiss A. S., Gallin J. I., Kaplan A. P. Fletcher factor deficiency. A diminished rate of Hageman factor activation caused by absence of prekallikrein with abnormalities of coagulation, fibrinolysis, chemotactic activity, and kinin generation. J Clin Invest. 1974 Feb;53(2):622–633. doi: 10.1172/JCI107597. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Wuepper K. D. Prekallikrein deficiency in man. J Exp Med. 1973 Dec 1;138(6):1345–1355. doi: 10.1084/jem.138.6.1345. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Ziegler J. B., Alper C. A., Rosen R. S., Lachmann P. J., Sherington L. Restoration by purified C3b inactivator of complement-mediated function in vivo in a patient with C3b inactivator deficiency. J Clin Invest. 1975 Mar;55(3):668–672. doi: 10.1172/JCI107975. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES